Mystery illness after COVID shot? new study seeks answers

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

General Criteria (apply to all study parts: PROGRESS, ENDOCLOT, REAL, patients and matched healthy controls) Inclusion Criteria 1. Age ≥ 18 years 2. Sufficient knowledge of German to complete study-related questionnaires and procedures Exclusion Criteria 1. Severe cognitive, physical impairment or psychiatric conditions impeding participation 2. Active oncological disease or immunosuppressive 3. Known pregnancy at the time of enrolment PROGRESS (patients only) Inclusion Criteria 1. Coded participation with online consent confirmation 2. Self-reported onset of persistent symptoms temporally associated with a COVID-19 vaccination 3. Willingness and ability to participate in the 8-month follow-up period Exclusion Criteria 1\. No specific exclusion criteria for this part ENDOCLOT and REAL (patients and matched healthy controls) Inclusion Criteria 1. Signed informed consent form 2. For patients: 1. Receipt of at least one COVID-19 vaccination 2. Onset of new, otherwise unexplained symptoms within 0-14 days after vaccination 3. Persistence of symptoms for at least 6 months following vaccination 4. Selection is based on a diagnosis of ME/CFS according to the Canadian Consensus Criteria (CCC) and PEM. 2\. For controls: History of COVID-19 vaccination without persistent adverse effects; age (+/- 10 years), and sex match to a corresponding case Exclusion Criteria (patients and matched healthy controls) 1. Clinically suspected or laboratory confirmed SARS-CoV-2 infection after vaccination or temporally related to symptom onset. 2. Concurrent pre-existing Long COVID symptoms, obtained from the patient´s history 3. Any self-reported or uncertain history of an acute infectious event (including mild or subclinical infections) in temporal proximity to COVID-19 vaccination 4. Known pre-existing medical conditions or ongoing medications that could plausibly explain the reported symptoms (e.g., preexisting ME/CFS, POTS, fibromyalgia, small-fiberneuropathy, autoimmune disease with systemic involvement or other chronic multisystemic dysautonomia syndromes) 5. Use of long-term, high-dose anti-inflammatory